Polyethylene glycol-interferon alpha conjugates for therapy of infection

An interferon alpha, mammalian technology, applied in drug combinations, antiviral agents, anti-infectives, etc., can solve problems such as limiting the therapeutic effect of interferon alpha

Inactive Publication Date: 2000-08-02
SCHERING AG
View PDF14 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Unwanted side effects associated with interferon-alpha therapy and the burden of three weekly injections often limit the therapeutic efficacy of interferon-alpha

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] The present invention relates to a method for treating diseases that are sensitive to treatment with interferon alpha, and the present invention has unexpectedly found that interferon alpha (hereinafter referred to as "PEG" combined with polyethylene glycol with a molecular weight of 12000 12000 -IFNα") can enhance the therapeutic effect, while greatly reducing (or completely eliminating) the adverse side effects usually caused by the implementation of interferon-α treatment regimens. In particular, it has been surprisingly found that combining PEG 12000 - Once-weekly administration of IFNα-2b conjugates to patients with chronic hepatitis C has the same or increased therapeutic effect, while at the same time greatly reducing or eliminating the side effects usually caused by the implementation of interferon-α treatment regimens.

[0017] A typical dose of interferon alpha for the treatment of human HCV is 3 million international units three times per week ("3 MIU TIW"). ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method comprising administering a PEG12000-IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.

Description

[0001] Cross-references to related applications [0002] This PCT application claims priority to U.S. Application Serial No. 08 / 839,101, filed April 29, 1997, which is a continuation-in-part of Application Serial No. 08 / 742,305, filed November 1, 1996, which Also continuation of Provisional Application Serial No. 60 / 006,130, filed November 2, 1995, the disclosure of which is hereby incorporated by reference in its entirety. Background of the invention [0003] The invention relates to a method for treating viral infectious diseases, especially a method for treating viral infections sensitive to interferon alpha, the method comprising administering a certain amount of polyethylene glycol-interferon alpha conjugate (polyethylene glycol-interferon alpha conjugate ), the therapeutic dose can effectively treat viral infectious diseases and can reduce or eliminate the adverse side effects usually caused by the administration of interferon α....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61K38/19A61K38/21A61K47/48A61P31/12
CPCA61K47/48215A61K38/212A61K47/60A61P31/00A61P31/12A61K47/50
Inventor P·格吕D·L·库特勒M·B·阿夫里梅
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap